A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients With Select Autoimmune Rheumatic Diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs DR-0201 (Primary)
Indications Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Sjogren's syndrome; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors Dren Bio

10 Dec 2024 Planned End Date changed from 1 Nov 2026 to 1 Dec 2026.
10 Dec 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Dec 2026.
10 Dec 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com